936727-68-3 Usage
Uses
Used in Pharmaceutical Development:
N-(6-chloro-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane-1-carboxamide is used as a candidate for pharmaceutical development due to its potential interactions with biological targets. Its unique structure allows for the possibility of being tailored for specific therapeutic applications, making it valuable in the creation of new drugs.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, N-(6-chloro-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane-1-carboxamide serves as a subject of research to understand its interactions with biological systems. Its structural components may provide insights into the design of new molecules with desired pharmacological properties, contributing to the advancement of drug discovery and development processes.
Used in Drug Design:
N-(6-chloro-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane-1-carboxamide is utilized in drug design for its potential to be modified and optimized for specific medical uses. Its cyclopropane carboxamide, pyridinyl, and difluorobenzodioxol groups offer a foundation for creating molecules that can target particular biological pathways or receptors, potentially leading to the development of effective treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 936727-68-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,6,7,2 and 7 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 936727-68:
(8*9)+(7*3)+(6*6)+(5*7)+(4*2)+(3*7)+(2*6)+(1*8)=213
213 % 10 = 3
So 936727-68-3 is a valid CAS Registry Number.
936727-68-3Relevant academic research and scientific papers
SOLID FORMS OF LUMACAFTOR, ITS SALTS AND PROCESSES THEREOF
-
Page/Page column 55-56, (2017/11/04)
Aspects of the present application relate to solid forms of Lumacaftor, its salts and processes thereof. Specific aspects of the present application relate to alternate processes for the preparation of Lumacaftor and intermediates thereof. Present application further relates to the solid forms of Lumacaftor and its salts.
PROCESS FOR PREPARATION OF LUMACAFTOR
-
Paragraph 0177, (2017/05/07)
The present invention relates to a process for the preparation of amorphous lumacaftor. The present invention relates to a process for the preparation of intermediate 6-amino-2- halo-3-methylpyridine compounds used in the preparation of lumacaftor. The present invention relates to lumacaftor hydrobromide, process for its preparation and conversion thereof to lumacaftor.
PYRIDYL DERIVATIVES AS CFTR MODULATORS
-
Page/Page column 44, (2009/10/06)
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
MODULATORS OF CFTR
-
Page/Page column 90, (2009/01/20)
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.
